-
Nov 26, 2024 | 
radcliffecardiology.com | Harriette Van Spall |Andrew Coats |Julia Grapsa
AHA Conference 2024 - Discover the findings from a new study on the impact of diastolic dysfunction on the efficacy of empagliflozin in heart failure in the EMPEROR-Preserved trial. Prof Andrew Coats (Heart Research Institute, New South Wales, AU) joins us onsite at AHA Conference to discuss findings from a new analysis of diastolic dysfunction in the EMPEROR-Preserved trial (NCT03057951).
-
Nov 19, 2024 | 
radcliffecardiology.com | Harriette Van Spall |Mikhail Kosiborod |Julia Grapsa |Milind Y. Desai
AHA Conference 2024 — REALIZE-K: Impact of sodium zirconium cyclosilicate (SZC) on HFrEF patient's potassium levels whilst on spironolactone. Late-Breaker Host, Dr Harriette Van Spall (McMaster University, CA) is joined onsite by Dr Mikhail Kosiborod (Saint Luke's Mid America Heart Institute, US) to discuss the findings from the REALIZE-K Study (NCT04676646; AstraZeneca).
-
Nov 19, 2024 | 
radcliffecardiology.com | Harriette Van Spall |Mikhail Kosiborod |Julia Grapsa |Milind Y. Desai
AHA Conference 2024 — REALIZE-K: Impact of sodium zirconium cyclosilicate (SZC) on HFrEF patient's potassium levels whilst on spironolactone. Late-Breaker Host, Dr Harriette Van Spall (McMaster University, CA) is joined onsite by Dr Mikhail Kosiborod (Saint Luke's Mid America Heart Institute, US) to discuss the findings from the REALIZE-K Study (NCT04676646; AstraZeneca).
-
Sep 11, 2024 | 
radcliffecardiology.com | Richard E. Pratley |Phyo T. Htoo |Julia Grapsa |Marta Sitges
Skip to main content Video Published: Views: 14 Likes: 0 Average (ratings) EASD 24 - Dr Phyo Htoo (Harvard Medical School, Boston, MA, US) joins us to discuss a study investigating the comparative effectiveness of empagliflozin and glucagon-like peptide-1 receptor agonists in combination as compared to either medication alone in patients with type 2 diabetes. Interview Questions:1. What was the reasoning for this study? 2.
-
Sep 11, 2024 | 
radcliffecardiology.com | Richard E. Pratley |Julia Grapsa |Marta Sitges |Alison J Duncan
Skip to main content Video Published: Views: 22 Likes: 0 Average (ratings) EASD 24 - We are joined by Dr Richard Pratley (AdventHealth Diabetes Institute, US) to discuss the kidney, cardiovascular, metabolic, mortality and safety results from the FLOW trial. Interview Questions:1. What is the reasoning behind the FLOW Trial? 2. What was the patient population and study design? 3. What are the key results? 4.
-
Sep 9, 2024 | 
radcliffecardiology.com | Joost Daemen |David Erlinge |Julia Grapsa |Marta Sitges
Video Published: Views: 53 Likes: 0 Average (ratings) One-year outcomes from INFINITY-SWEDEHEART RCT recently presented at ESC 2024 demonstrated that DynamX Bioadaptor meets primary endpoint and significantly reduces adverse events compared to DES after six months. Dr David Erlinge, the primary investigator of INFINITY-SWEDEHEART RCT, shares a quick summary of the one-year outcomes presented at ESC 2024.
-
Sep 6, 2024 | 
radcliffecardiology.com | John McMurray |Richard E. Pratley |Julia Grapsa |Marta Sitges
Skip to main content Video Published: Views: 9 Likes: 0 Average (ratings) Join Prof Atul Pathak (Clinique Pasteur, FR) and Prof Sofie Brouwers (Olv Hospital Aalst, BE) in this video on 'Renal Denervation Takeaways From ESC Guidelines'. This video is supported by Related content
-
Aug 31, 2024 | 
radcliffecardiology.com | Harriette Van Spall |Mirvat Alasnag |Helene Eltchaninoff |Julia Grapsa
Video Published: Views: 11 Likes: 0 Average (ratings) ESC Congress 2024 — Transcatheter aortic valve replacement shows superiority over surgical aortic valve replacement for women with severe aortic stenosis. Host, Dr Harriette Van Spall (McMaster University, CA) sits down with Prof Helene Eltchaninoff (University Hospital of Rouen, FR) to discuss key findings from the RHEIA trial (NCT04160130; Optimapharm).
-
Aug 30, 2024 | 
pcronline.com | Julia Grapsa
Reported from ESC Congress 2024Julia Grapsa provides her take on the Chronic Coronary Syndromes (CCS) Guidelines which were presented by Felicita Andreotti and Christiaan Vrints at ESC Congress 2024 in London.
-
Aug 2, 2024 | 
radcliffecardiology.com | Mirvat Alasnag |Nicolas Van Mieghem |Joost Daemen |Julia Grapsa
Video Published: Views: 78 Likes: 1 Average (ratings) Which interventional cardiology studies will have the greatest impact at ESC 2024? Leading experts Prof Nicolas Van Mieghem and Dr Joost Daemen (Thoraxcenter, Erasmus MC, Rotterdam, NL) offer an exclusive preview of the most anticipated hot line studies set to be unveiled at ESC Congress 2024. Get their in-depth analysis of the studies and gain invaluable insights ahead of the curve.
